The aim of this retrospective study is to evaluate the efficacy and safety of intravenous immune globulin (IVIg) as immunomodulatory treatment in patients with inflammatory myopathies. We analyzed six patients, observed in a single-center from 2004 to 2012, affected by polymyositis (PM), dermatomyositis (DM) or inclusion body myositis (IBM) and treated with IVIg. IVIg has been successfully used as rescue therapy in all patients with a periodical dose of 1-2 g/Kg administered in 5 daysAll patients showed an improvement of muscle strength and a significant reduction of muscle enzyme levels (p<0.01 and p<0.05, respectively). Adverse events were mild and tolerable. Although IVIg has been demonstrated to be effective as steroid-sparing agent when other immunosuppressive drugs had failed, in all patients, however, a progressive reduction of clinical response after a variable number of IVIg cycles was observed. IVIg may safely be used and represents an effective rescue therapy in autoimmune myositis. Larger controlled studies are however needed to establish the IVIg actual efficacy in inflammatory myopathies, define standard therapeutic guidelines and detect predictive factors of response

Efficacy of ivig therapy in inflammatory myositis / Sunzini, Flavia; S., Salemi; Germano, Valentina; Crialesi, Dorotea; DI ROSA, Roberta; D'Amelio, Raffaele. - In: INTERNATIONAL TRENDS IN IMMUNITY. - ISSN 2326-3121. - 1:1(2013), pp. 40-43.

Efficacy of ivig therapy in inflammatory myositis

SUNZINI, FLAVIA;GERMANO, VALENTINA;CRIALESI, DOROTEA;DI ROSA, Roberta;D'AMELIO, Raffaele
2013

Abstract

The aim of this retrospective study is to evaluate the efficacy and safety of intravenous immune globulin (IVIg) as immunomodulatory treatment in patients with inflammatory myopathies. We analyzed six patients, observed in a single-center from 2004 to 2012, affected by polymyositis (PM), dermatomyositis (DM) or inclusion body myositis (IBM) and treated with IVIg. IVIg has been successfully used as rescue therapy in all patients with a periodical dose of 1-2 g/Kg administered in 5 daysAll patients showed an improvement of muscle strength and a significant reduction of muscle enzyme levels (p<0.01 and p<0.05, respectively). Adverse events were mild and tolerable. Although IVIg has been demonstrated to be effective as steroid-sparing agent when other immunosuppressive drugs had failed, in all patients, however, a progressive reduction of clinical response after a variable number of IVIg cycles was observed. IVIg may safely be used and represents an effective rescue therapy in autoimmune myositis. Larger controlled studies are however needed to establish the IVIg actual efficacy in inflammatory myopathies, define standard therapeutic guidelines and detect predictive factors of response
2013
IVIg; myositis; autoimmune diseases
01 Pubblicazione su rivista::01a Articolo in rivista
Efficacy of ivig therapy in inflammatory myositis / Sunzini, Flavia; S., Salemi; Germano, Valentina; Crialesi, Dorotea; DI ROSA, Roberta; D'Amelio, Raffaele. - In: INTERNATIONAL TRENDS IN IMMUNITY. - ISSN 2326-3121. - 1:1(2013), pp. 40-43.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/618216
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact